Global COVID-19 Recombinant Protein Vaccine Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends
Publisher : MRA | Format : PDF
Global COVID-19 Recombinant Protein Vaccine Market Insights, Forecast to 2034
Preparation and immunogenicity and immunoprotection of Hib polysaccharide conjugate vaccine based on pneumococcal surface adhesive (PsaA).Methods PsaA gene recombinant protein (rPsaA) was prepared by genetic engineering, and then conjugated with Hib polysaccharide by amide condensation.The 3-week-old mice were immunized with this vaccine, and mice were inoculated with tetanus toxoid and haemophilus influenzae type B (Hib) polysaccharide conjugate vaccine (hib-tt) as controls and phosphate buffer (PBS) as blank controls.
Market Analysis and InsightsGlobal COVID-19 Recombinant Protein Vaccine Market
The global COVID-19 Recombinant Protein Vaccine market is projected to grow from US$ million in 2023 to US$ million by 2033, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for COVID-19 Recombinant Protein Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2033, at a CAGR of % during the forecast period of 2023 through 2033.
The China market for COVID-19 Recombinant Protein Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2033, at a CAGR of % during the forecast period of 2023 through 2033.
The Europe market for COVID-19 Recombinant Protein Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2033, at a CAGR of % during the forecast period of 2023 through 2033.
The global key companies of COVID-19 Recombinant Protein Vaccine include GSK, Johnson & Johnson, Sanofi, Novavax, Pukang Biologic Technology, Clover Biopharmaceuticals and Suzhou Yuzhibo Biotechnology, etc. in 2023, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for COVID-19 Recombinant Protein Vaccine market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2023, estimates for 2023, and projections of CAGR through 2033.
This report researches the key producers of COVID-19 Recombinant Protein Vaccine, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for COVID-19 Recombinant Protein Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the COVID-19 Recombinant Protein Vaccine revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global COVID-19 Recombinant Protein Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2033. Evaluation and forecast the market size for COVID-19 Recombinant Protein Vaccine revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, Johnson & Johnson, Sanofi, Novavax, Pukang Biologic Technology, Clover Biopharmaceuticals and Suzhou Yuzhibo Biotechnology, etc.
GSK
Johnson & Johnson
Sanofi
Novavax
Pukang Biologic Technology
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology
Segment by Type
Being Developed
Preclinical
Clinical I
Clinical II
Pharmaceutical And Biotechnology Companies
Hospital
Academic And Research Organizations
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Revenue of COVID-19 Recombinant Protein Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3Detailed analysis of COVID-19 Recombinant Protein Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8China by type and by application revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, COVID-19 Recombinant Protein Vaccine revenue, gross margin, and recent development, etc.
Chapter 12Analyst's Viewpoints/Conclusions
Market Analysis and InsightsGlobal COVID-19 Recombinant Protein Vaccine Market
The global COVID-19 Recombinant Protein Vaccine market is projected to grow from US$ million in 2023 to US$ million by 2033, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for COVID-19 Recombinant Protein Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2033, at a CAGR of % during the forecast period of 2023 through 2033.
The China market for COVID-19 Recombinant Protein Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2033, at a CAGR of % during the forecast period of 2023 through 2033.
The Europe market for COVID-19 Recombinant Protein Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2033, at a CAGR of % during the forecast period of 2023 through 2033.
The global key companies of COVID-19 Recombinant Protein Vaccine include GSK, Johnson & Johnson, Sanofi, Novavax, Pukang Biologic Technology, Clover Biopharmaceuticals and Suzhou Yuzhibo Biotechnology, etc. in 2023, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for COVID-19 Recombinant Protein Vaccine market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2023, estimates for 2023, and projections of CAGR through 2033.
This report researches the key producers of COVID-19 Recombinant Protein Vaccine, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for COVID-19 Recombinant Protein Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the COVID-19 Recombinant Protein Vaccine revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global COVID-19 Recombinant Protein Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2033. Evaluation and forecast the market size for COVID-19 Recombinant Protein Vaccine revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, Johnson & Johnson, Sanofi, Novavax, Pukang Biologic Technology, Clover Biopharmaceuticals and Suzhou Yuzhibo Biotechnology, etc.
By Company
GSK
Johnson & Johnson
Sanofi
Novavax
Pukang Biologic Technology
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology
Segment by Type
Being Developed
Preclinical
Clinical I
Clinical II
Segment by Application
Pharmaceutical And Biotechnology Companies
Hospital
Academic And Research Organizations
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Revenue of COVID-19 Recombinant Protein Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3Detailed analysis of COVID-19 Recombinant Protein Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8China by type and by application revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, COVID-19 Recombinant Protein Vaccine revenue, gross margin, and recent development, etc.
Chapter 12Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices